Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty

Archives of Medical Science

Volumn 7, Issue 3, 2011, Pages 444-448

  Derkacz, Arkadiusz ^a   Protasiewicz, Marcin ^a   Porȩba, Rafał ^a   Doroszko, Adrian ^a   Porȩba, Małgorzata ^a   Antonowicz Juchniewicz, Jolanta ^a   Andrzejak, Ryszard ^a   Szuba, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Asymmetric dimethylarginine; Bare metal stent; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; N(G),N(G) DIMETHYLARGININE; SIMVASTATIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 79960439776     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.23410     Document Type: Article

References (27)

1. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2007; 100: 3K-9K.
2. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-8. (Pubitemid 29369253)
3. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493.e1-8.
4. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 2001; 358: 2127-8. (Pubitemid 34094905)
5. Chan AW, Moliterno DJ. Restenosis: The clinical issues. In: Topol EJ (ed.) Texbook of Interventional Cardiology. Philadelphia: Elsevier Science 2003; 415-54.
6. Ari H, Ari S, Erdoǧan E, et al. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart Vessels 2010; 25: 19-26.
7. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24: 1912-9.
8. Johansen O, Abdelnoor M, Brekke M, Seljeflot I, Hostmark AT, Arnesen H. Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables. Scand Cardiovasc J 2001; 35: 86-91.
9. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7. (Pubitemid 28509278)
10. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-9. (Pubitemid 27344855)
11. Stuehlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75. (Pubitemid 33104795)
12. Surdacki A, Nowicki M, Sandman J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-8. (Pubitemid 29164831)
13. Mizayaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6. (Pubitemid 29120084)
14. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105. (Pubitemid 30616904)
15. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51. (Pubitemid 38234494)
16. Cipollone F, Fazia M, Iezzi A, et al. High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis. Heart 2003; 89: 773-9. (Pubitemid 36760641)
17. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-95.
18. Radomski M, Palmer R, Moncada S. Endogenous nitric oxide inhibits platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-8. (Pubitemid 17154788)
19. Garg U, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic-guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7. (Pubitemid 19124139)
20. Fishman J, Ryan G, Karnovsky M. Endothelial regeneration in rat carotid artery and the significance of endothelial denudaion in the pathogenesis of myointimal thickening. Lab Invest 1975; 32: 339-51.
21. Maffia P, Ianaro A, Sorrentino R. Beneficial Effects of NO-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis. Atheroscler Thromb Vasc Biol 2002; 22: 263-7. (Pubitemid 34127037)
22. Kitta Y, Nakamura T, Kodama Y, et al. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. J Am Coll Cardiol 2005; 46: 648-55. (Pubitemid 41132692)
23. Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005; 111: 70-5. (Pubitemid 40070846)
24. Thanyasiri P, Kathir K, Celermajer DS, Adams MR. Endothelial dysfunction and restenosis following percutaneous coronary intervention. Int J Cardiol 2007; 119: 362-7. (Pubitemid 46921269)
25. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine causes arteriosclerotic lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-8. (Pubitemid 39180895)
26. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: An insight into the pathophysiological significance of raised plasma ADMA. PLoS Med 2005; 2: e264.
27. Aktoz M, Aktoz T, TatlI E, et al. Asymmetrical dimethylarginine and severity of erectile dysfunction and their impact on cardiovascular events in patients with acute coronary syndrome. Arch Med Sci 2010; 6: 168-75.